Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

BACKGROUND: Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PFS) and overall survival (OS) with first-line anti-PD1 (PD1]+anti-CTLA-4 (IPI) versus PD1. Whether this is also true after BRAF/MEKi therapy is unknown. We aimed to determine the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pires da Silva, Ines, Zakria, Danny, Ahmed, Tasnia, Trojanello, Claudia, Dimitriou, Florentia, Allayous, Clara, Gerard, Camille, Zimmer, Lisa, Lo, Serigne, Michielin, Olivier, Lebbe, Celeste, Mangana, Johanna, Ascierto, Paolo Antonio, Johnson, Douglas B, Carlino, Matteo, Menzies, Alexander, Long, Georgina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263926/
https://www.ncbi.nlm.nih.gov/pubmed/35798536
http://dx.doi.org/10.1136/jitc-2022-004610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263926/
https://www.ncbi.nlm.nih.gov/pubmed/35798536
http://dx.doi.org/10.1136/jitc-2022-004610

Ejemplares similares